Loading...
Market
What will be the outcome of FDA review on the safety of Ozempic and Wegovy in relation to NAION by end of 2024?
2
Resolution / Starting Odds
No action taken • 25%
Warning issued • 25%
Recall issued • 25%
Label change required • 25%
FDA official announcements or press releases
Story
Harvard Study Reveals Link Between Ozempic, Wegovy and Serious Eye Condition NAION
Jul 3, 2024, 03:06 PM
A new study by Massachusetts Eye and Ear has revealed a potential link between Novo Nordisk’s GLP-1 drugs, Ozempic and Wegovy, and a serious eye condition called nonarteritic anterior ischemic optic neuropathy (NAION), which can cause vision loss. The study indicates that patients prescribed these drugs for diabetes or weight loss had a higher risk of developing NAION than those not on the medication. This research, published on Wednesday, is the first to establish this connection. The findings have raised concerns about the safety of these widely popular weight-loss and diabetes treatments. The study involved 710 type 2 diabetes patients and was conducted in collaboration with Harvard.
View original story
Similar markets
Yes • 50%
No • 50%
Yes • 50%
No • 50%
Confirms link • 25%
Refutes link • 25%
Inconclusive • 25%
No publication • 25%
Yes • 50%
No • 50%
Ban the drugs • 25%
Issue safety warnings • 25%
No action taken • 25%
Other actions • 25%
Confirms significant risk • 25%
No significant risk found • 25%
Inconclusive results • 25%
Study retracted • 25%
Yes • 50%
No • 50%